Aarti Drugs Q1 FY27 Earnings Call — Analysis (NSE: AARTIDRUGS)
Aarti Drugs Q1 FY27 revenue up 19% YoY to ₹703.6 Cr, EBITDA margin expands 120 bps to 13.8%, driven by strong API realizations amid geopolitical disruptions and Sayakha ramp-up.
The take
Q1FY27 Consolidated Revenue ₹703.6 Cr ( +19% YoY ) . New guidance — FY28 metformin capacity expansion an… 2,200 tons per month . New story: Backward integration ramp-up at Sayakha .
Results
Consolidated revenue ₹703.6 Cr, +19% YoY; EBITDA ₹96.9 Cr +30% YoY, margin 13.8% (+120bps); PAT ₹50.1 Cr (adjusted +29% YoY, reported decline due to high base tax refund).
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Consolidated Revenue | ₹703.6 Cr | +19% | yoy · Q1FY27 |
| EBITDA | ₹96.9 Cr | +30% | yoy · Q1FY27 |
| EBITDA Margin | 13.8% | +120bps | yoy · Q1FY27 |
| PBT | ₹69.2 Cr | +35% | yoy · Q1FY27 |
| PAT (reported) | ₹50.1 Cr | yoy · Q1FY27 · Q1FY26 PAT ₹54.0 Cr included ₹15 Cr tax refund; ex. that growth 29% | |
| Standalone Revenue | ₹627.6 Cr | +20% | yoy · Q1FY27 |
| Formulations Revenue | ₹81.6 Cr | +8% | yoy · Q1FY27 |
| Specialty Chemicals Sales | ₹82 Cr | +149% | yoy · Q1FY27 |
| Aggregate Volume Growth | 3.5% | yoy · Q1FY27 · aggregate volume growth | |
| Aggregate Price Growth | 16-17% | yoy · Q1FY27 · aggregate price growth |
Guidance
Management targets 10-15% annual volume growth over next two years; expects EBITDA margin to reach 15% once greenfield utilization improves and Salicylic acid losses abate; captive intermediate supply from Sayakha to hit 80-90% by Dec quarter.
What management committed to
- We will scale Metformin capacity from 1,400 tons per month to 2,200 tons per month, with a dedicated USFDA block of 500-550 tons per month, within roughly 10 to 12 months, and then file for USFDA inspection to begin supplies to the US market. — 2,200 tons per month, FY28
- Captive consumption of intermediates from the Sayakha facility for antidiabetic products will increase to 80-90% of total requirement by the December quarter (Q3FY27). — 80-90%, Q3FY27
- Phase 2 brownfield capex at Sayakha and Tarapur will deliver asset turnover of around 3x to 4x once operational. — 3-4x
- Aarti Drugs expects to achieve 10% to 15% annual volume growth over the next two years (FY27 and FY28), driven by existing capacity ramp-up and new products. — 10-15%, FY28
- EBITDA margin will reach 15% as greenfield utilization improves and the Salicylic acid plant drag reduces. — 15%
- Anti-dumping duty on salicylic acid imports is expected to be imposed in about 1 year, after the government's injury period extension. — Q2FY28
Key themes
Geopolitical API pricing tailwinds and backward integration ramp-up
How the narrative shifted
- Geopolitical disruption boosts API realizations: Management highlights that the West Asia conflict created a favorable pricing environment, pushing API realizations significantly higher and reinforcing the value of supply reliability.
- Backward integration ramp-up at Sayakha: Sayakha facility is rapidly increasing captive intermediate supply, reducing external procurement and enhancing gross margin control for the antidiabetic segment.
- Regulatory unlocking into US and EU markets: The company is actively pursuing USFDA approvals for APIs and formulations to shift towards higher-margin regulated markets, with near-term catalysts in metformin and E-22 plant.
- Salicylic acid drag and anti-dumping wait: Salicylic acid plant operated at minimal volumes; management is pivoting to derivatives to stem losses while anti-dumping duty decision is delayed by a year.
- Spec Chem volume surge and capacity utilisation: Specialty Chemicals sales jumped 149% YoY driven by new capacities, with methylamine at 65% utilisation and a quarterly run-rate expected to sustain and improve.
- Disciplined capex with increasing returns: Phase 1 greenfield capex yielded 1.5x asset turn; Phase 2 brownfield expansions are expected to deliver 3-4x due to common infrastructure, reinforcing a disciplined growth approach.
- Operational resilience amid supply chain volatility: Manufacturing facilities ran without disruptions despite global logistics and raw material volatility, reflecting strong inventory management and backward integration.
Operational commentary
- Sayakha facility utilization reached 65%; captive intermediate supply for antidiabetics to hit 80-90% by December quarter, expected to add ~1% to gross margins at peak.
- Metformin capacity expansion from 1,400 tpm to 2,200 tpm initiated, including a 500–550 tpm USFDA block at Sarigam; US supplies to begin after inspection in ~12 months; European demand contingent on USFDA approval.
- E-22 USFDA plant currently supplies 4–5 products to EU; US business development underway with sample approvals; new quasi-greenfield expansion planned to double USFDA capacity with 3 additional lines.
- Salicylic acid operations: low production (67 tonnes) in Q1; newly commissioned derivative plant (methyl salicylate, 350–400 tpm) to mitigate losses; anti-dumping duty expected in ~1 year, making derivatives currently more profitable.
- Formulations brownfield expansion at Baddi progressing to double OSD capacity; exports already 74% of formulation revenue.
- Specialty Chemicals drove volume growth; methylamine plant at 65% utilisation (3,500 tonnes in Q1); quarterly run rate expected to sustain and improve.
- Regulatory: 9 CEPs for European markets; USFDA approval for oncology formulations; API facility USFDA filing after Metformin block will unlock regulated market sales.
Analyst Q&A
Q. Metformin pricing movement and backward integration strategy to gain market share.
Metformin prices up 15-20% vs pre-war; capacity being scaled to 2,200 tpm with dedicated USFDA block; US market entry after 12 months; European large customers require USFDA approval, so dual filing to open both markets.
Q. Has the API industry entered a sustained recovery, and what is the expected asset turnover from the ₹600 Cr capex?
Environment remains volatile, but Aarti's product portfolio is insulated from Chinese competition. Phase 1 greenfield asset turn ~1.5x; Phase 2 brownfield will deliver 3-4x due to shared infrastructure.
Q. Clarification on metformin expansion location, E-22 USFDA plant supplies, Specialty Chemicals run-rate, and Salicylic acid plant outlook.
Metformin expansion at Sarigam; E-22 currently supplies 4-5 products to EU; Spec Chem quarterly run-rate sustainable and improving; Salicylic acid output low, derivatives plant commissioned to reduce losses, anti-dumping duty expected in ~1 year.
Q. Sustainability of 14% plus EBITDA margin if realizations cool down, and volume growth aspirations after large capex.
At 14% already; 15% achievable as greenfield utilisation rises and Salicylic acid drag reduces. 10-15% annual volume growth doable for next two years even if salicylic issues persist.
Q. How much of Sayakha's benefit is visible in margins today and what incremental gross margin uplift from captive consumption?
Current captive share ~30-40%, rising to 80-90% by December quarter; peak gross margin uplift expected around 1%.
Research and educational content only. Not investment advice.